Sustained resolution of enthesitis and peripheral arthritis over 104 weeks with bimekizumab in axial spondyloarthritis
RMD Open 2025;11:e005969 Doi: 10.1136/rmdopen-2025-005969
Ramiro et al. show that bimekizumab (BKZ) reduces enthesitis and peripheral arthritis in patients with nr-axSpA and r-axSpA up to 2 years. Authors assessed the effect of BKZ treatment on the main peripheral manifestations of axSpA, including enthesitis and peripheral arthritis, using a range of measures including DAPSA, to Week 104 in the BE MOBILE 1 and 2 studies.